Israeli biotechnology company Can-Fite BioPharma Ltd. is looking to raise $5 million via the sale of 3,333,336 American depositary shares priced at $1.50 each.
The offering will close by March 13 with H.C. Wainwright & Co. acting as the exclusive placement agent in the offering.
Can-Fite is advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases.
